OncoMatch/Clinical Trials/NCT06756932
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Is NCT06756932 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BGB-21447 and Fulvestrant for hormone-receptor-positive breast cancer.
Treatment: BGB-21447 · Fulvestrant · BGB-43395 — This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 hormone receptor positive
HR+
Required: HER2 (ERBB2) negative
HER2-
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: endocrine therapy — adjuvant or advanced/metastatic
including prior endocrine therapy
Must have received: CDK4/6 inhibitor — adjuvant or advanced/metastatic
including prior...CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting
Cannot have received: BCL2 inhibitor
Prior Bcl-2 inhibitor exposure
Cannot have received: CDK4 inhibitor
Exception: For triplet combination cohorts only
For triplet combination cohorts only: Prior therapy selectively targeting CDK4
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hoag Memorial Presbyterian · Newport Beach, California
- University of Iowa Hospitals and Clinics · Iowa City, Iowa
- Md Anderson Cancer Center · Houston, Texas
- Fred Hutchinson Cancer Research Center · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify